Comparison of latanoprost monotherapy and combined therapy of 0.5% timolol and 1% dorzolamide in chronic primary angle-closure glaucoma (CACG) in Japanese patients

Journal of Ocular Pharmacology and Therapeutics

Volumn 21, Issue 6, 2005, Pages 483-489

  Sakai, Hiroshi ^a   Shinjyo, Sayo ^a   Nakamura, Yoshimi ^a   Nakamura, Yuko ^a   Ishikawa, Shusaku ^a   Sawaguchi, Shoichi ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; BETAXOLOL; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; PILOCARPINE; TIMOLOL;

ADULT; AGED; ARTICLE; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; IRIDOTOMY; JAPAN; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTIHYPERTENSIVE AGENTS; CHRONIC DISEASE; DRUG COMBINATIONS; FEMALE; GLAUCOMA, ANGLE-CLOSURE; HUMANS; INSTILLATION, DRUG; INTRAOCULAR PRESSURE; JAPAN; MALE; OPHTHALMIC SOLUTIONS; PATIENT COMPLIANCE; PROSTAGLANDINS F, SYNTHETIC; SULFONAMIDES; THIOPHENES; TIMOLOL;

EID: 30544440735     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2005.21.483     Document Type: Article

References (29)

1. Yamamoto, T., Iwase, A., Araie, M., et al. and the Tajimi Study Group, Japan Glaucoma Society. The Tajimi study report 2 prevalence of primary angle closure and secondary glaucoma in a Japanese population. Ophthalmology 112:Epub ahead of print, 2005.
2. Foster, P.J., Baasanhu, J., Alsbirk, P.H., et al. Glaucoma in Mongolia. A population-based survey in Hovsgol province, northern Mongolia. Arch. Ophthalmol. 114:1235-1241, 1996.
3. Alsagoff, Z., Aung, T., Ang, L.P., et al. Long-term clinical course of primary angle-closure glaucoma in an Asian population. Ophthalmology 107:2300-2304, 2000.
4. Hung, P.T., Hsieh, J.W., Chen, Y.F., et al. Efficacy of latanoprost as an adjunct to medical therapy for residual angle-closure glaucoma after iridectomy. J. Ocul. Pharmacol. Ther. 16:43-46, 2000.
5. Toris, C.B., Camras, C.B., and Yablonski, M.E. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology 100:1297-1304, 1993.
6. Ziai, N., Dolan, J.W., Kacere, R.D., et al. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analog, after topical application in normal and ocular hypertensive human eyes. Arch. Ophthalmol. 111:1351-1358, 1993.
7. Alm, A., Villumsen, J., Tornquist, P., et al. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study. Ophthalmology 100:1316-1317, 1993.
8. Alm A., and Stjernschantz, J. Effects on intraocular pressure and side-effects of 0.005% latanoprost applied once-daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 102:1743-1752, 1995.
9. Mishima, H., Masuda, K., and Araie, M. Phase III clinical trial of PhXA41 (latanoprost) in primary open-angle glaucoma and ocular hypertension. Jpn. J. Clin. Ophthalmol. 90:607-615, 1996.
10. Emmerich, K.H. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension. A 3-month randomized study. Graefes' Arch. Clin. Exp. Ophthalmol. 238:19-23, 2000.
11. Chew, P.T., Aung, T., Aquino, M.V., et al., for the EXACT Study Group. Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma. Ophthalmology 111:427-434, 2004.
12. Sakai, H., Morine-Shinjyo, S., Shinzato, M., et al. Uveal effusion in primary angle-closure glaucoma. Ophthalmology 112:413-419, 2005.
13. Tane, S., Sujino, T., Tuchiya, M., et al. Ultrasound biomicroscopic imaging diagnosis of the anterior segment of the eye with high-frequency ultrasonic diagnostic equipment. Nippon Ganka Gakkai Zasshi 99:1254-1258, 1995.
14. Kobayashi, H., and Kobayashi, K. Quantitative comparison of Zeiss-Humphrey model 840 and Rion UX-02 systems of ultrasound biomicroscopy. Graefes' Arch. Clin. Exp. Ophthalmol. 237:381-386, 1999.
15. Mao, L.K., Stewart, W.C., and Shields, M.B. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am. J. Ophthalmol. 111:51-55, 1991.
16. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 130:429-440, 2000.
17. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am. J. Ophthalmol. 126:498-505, 1998.
18. Heijl, A., Leske, M.C., Bengtsson, B., et al. Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 120:1268-1279, 2002.
19. Kass, M.A., Heuer, D.K., Higginbotham, E.J., et al. The Ocular Hypertension Treatment Study. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120:701-713, 2002.
20. Honrubia, P.M., Larsson, L.I., and Spiegel, D. A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma. Acta. Ophthalmol. Scand. 80:635-641, 2002.
21. Fechtner, R.D., Airaksinen, P.J., Getson, A.J., et al. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: Results from two randomized clinical trials. Acta. Ophthalmol. Scand. 82:42-48, 2004.
22. Susanna, R., and Sheu, W.P. for the Latin Ameriica Glaucoma Society. Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: An eight-week, randomized, open-label, parallel-group, multicenter study in Latin America. Clin. Ther. 26:755-768, 2004.
23. Janulevicine, I., Harris, A., Kagemann, L., et al. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients. Acta. Ophthalmol. Scand. 82:730-737, 2004.
24. Aung, T., Chan, Y.H., Chew, P.T., and the EXACT Study Group. Degree of angle closure and the intraocular pressure-lowering effect of latanoprost in subjects with chronic angle-closure glaucoma. Ophthalmology 112:267-271, 2005.
25. Camras, C.B., Way, M.B., Ritch, R., et al. Latanoprost treatment for glaucoma: Effects of treating for 1 year and of switching from timolol. U.S. latanoprost study group. Am. J. Ophthalmol. 126:390-399, 1998.
26. Grierson, I., Jonsson, M., and Cracknell, K. Latanoprost and pigmentation. Jpn. J. Ophthalmol. 48:602-612, 2004.
27. Mishima, H.K., Shoge, K., Takamatsu, M., et al. Ultrasound biomicroscopic study of ciliary body thickness after topical application of pharmacologic agents. Am. J. Ophthalmol. 121:319-321, 1996.
28. Sakai, H., Sakima, N., Nakamura, Y., et al. Ciliochoroidal effusion induced by topical latanoprost in a patient with Sturge-Weber syndrome. Jpn. J. Ophthalmol. 46:553-555, 2002.
29. Alimgil, M.L., and Benian, O. Choroidal effusion and shallowing of the anterior chamber after adjunctive therapy with latanoprost in a trabeculectomized patient with angle closure glaucoma. Int. Ophthalmol. 24:129-131, 2001.